FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:1895-1896 May 3, 2007 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

To the Editor: In this issue of the Journal, Black et al.¹ report on a significant increase in the risk of serious atrial-fibrillation adverse events (defined as events resulting in hospitalization or disability or judged to be life-threatening) associated with once-yearly infusions of intravenous zoledronic acid for the treatment of osteoporosis in postmenopausal women. However, there was no increased risk of all adverse events of atrial fibrillation with such infusions.

We reviewed the results of the Fracture Intervention Trial (FIT), a randomized study of alendronate sponsored by Merck, which involved 6459 postmenopausal women (mean age, 69 years).^2,3 The University . . . [Full Text of this Article]

This article has been cited by other articles:

• Heckbert, S. R., Li, G., Cummings, S. R., Smith, N. L., Psaty, B. M. (2008). Alendronate, Osteoporosis, and Atherosclerosis--Reply. Arch Intern Med 168: 2387-2387 [Full Text]  
• Qaseem, A., Snow, V., Shekelle, P., Hopkins, R. Jr., Forciea, M. A., Owens, D. K., for the Clinical Efficacy Assessment Subcommittee, (2008). Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians. ANN INTERN MED 149: 404-415 [Abstract] [Full Text]  
• (2008). A Once-Yearly IV Bisphosphonate for Osteoporosis. Obstet Gynecol 111: 1208-1209 [Full Text]  
• Cauley, J. A., Ensrud, K. E. (2008). Considering Competing Risks . . . Not All Black and White. Arch Intern Med 168: 793-795 [Full Text]  
• Heckbert, S. R., Li, G., Cummings, S. R., Smith, N. L., Psaty, B. M. (2008). Use of Alendronate and Risk of Incident Atrial Fibrillation in Women. Arch Intern Med 168: 826-831 [Abstract] [Full Text]  
• Sorensen, H. T., Christensen, S., Mehnert, F., Pedersen, L., Chapurlat, R. D, Cummings, S. R, Baron, J. A (2008). Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 336: 813-816 [Abstract] [Full Text]  
• Majumdar, S. R (2008). Oral bisphosphonates and atrial fibrillation. BMJ 336: 784-785 [Full Text]  
• MacLean, C., Newberry, S., Maglione, M., McMahon, M., Ranganath, V., Suttorp, M., Mojica, W., Timmer, M., Alexander, A., McNamara, M., Desai, S. B., Zhou, A., Chen, S., Carter, J., Tringale, C., Valentine, D., Johnsen, B., Grossman, J. (2008). Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis. ANN INTERN MED 148: 197-213 [Abstract] [Full Text]  
• de Nijs, R. N.J., Westgeest, A. A.A., Poole, K. E.S., Kaptoge, S., Reeve, J., Karam, R., Camm, J., McClung, M., Najib, M. A., Aziz, I., Chang, J. T., Black, D., Eriksen, E., Sellmeyer, D., Compston, J. (2007). Yearly zoledronic acid in postmenopausal osteoporosis.. NEJM 357: 711-712 [Full Text]  
• Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., Mautalen, C., Mesenbrink, P., Hu, H., Caminis, J., Tong, K., Rosario-Jansen, T., Krasnow, J., Hue, T. F., Sellmeyer, D., Eriksen, E. F., Cummings, S. R., the HORIZON Pivotal Fracture Trial, (2007). Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. NEJM 356: 1809-1822 [Abstract] [Full Text]  
• Compston, J. (2007). Treatments for Osteoporosis -- Looking beyond the HORIZON. NEJM 356: 1878-1880 [Full Text]